Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DTC Advertising Does Not Elicit Patient Requests For Prescriptions, Study Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The study “challenges many of the assumptions of both academic and public policy critics of DTC,” CommonHealth concludes.

You may also be interested in...



PhRMA DTC Principles Call For End Of Reminder Ads

Independent review panel will be established to handle complaints about pharmaceutical advertising.

Sen. Frist's Diagnosis On DTC: GAO Report, Two-Year Moratorium For New Drugs

Majority Leader Frist requests Government Accountability Office examine FDA's oversight of direct-to-consumer ads and their impact on drug usage and costs. The senator also requests drug companies voluntarily restrict DTC ads during the first two years a product is on the market.

Celgene To Submit Revlimid Phase III Special Protocol Assessment For CLL To FDA Shortly

Firm notes strong uptake of the product in 2006, as well as more than $400 million in Thalomid sales for the year during earnings call.

Topics

UsernamePublicRestriction

Register

PS064804

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel